ESC 365 - Panel discussion - Improving CV outcomes in type 2 diabetes: A novel role for GLP-1 receptor agonists?

Back

Open Access

Panel discussion - Improving CV outcomes in type 2 diabetes: A novel role for GLP-1 receptor agonists?

Session: Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?

Topic: Diabetes, dysglycaemia and metabolic syndrome

Speaker: Professor L. Ryden (Stockholm, SE) Doctor J. Plutzky (Boston, US) Professor N. Poulter (London, GB)

About the speakers

Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)

37 presentations

1 follower

Doctor Jorge Plutzky

Brigham and Women's Hospital, Boston (United States of America)

5 presentations

0 follower

Professor Neil Poulter

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

27 presentations

0 follower

4 more presentations in this session

Introduction: cardiovascular disease in type 2 diabetes – Where do we come from.

Speaker: Professor L. Ryden (Stockholm, SE)

Access

Slides

Video

Cardiovascular effects of GLP-1 receptor agonists.

Speaker: Doctor J. Plutzky (Boston, US)

Access

Slides

Video

Results from the LEADER cardiovascular outcomes trial.

Speaker: Professor N. Poulter (London, GB)

Access

Slides

Video

Perspectives on results from recent CVOTs in type 2 diabetes.

Speaker: Professor L. Ryden (Stockholm, SE)

Access

Slides

Video

Access the full session

Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?

Speakers: Professor L. Ryden, Doctor J. Plutzky, Professor N. Poulter, Professor L. Ryden, Doctor J. Plutzky...

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources